# Avego Management

> Avego Management is a VC fund backing Biotechnology and Pharmaceutical. See 8 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Alpharetta, United States
- Total investments: 8
- Last investment: Jan 2026
- Lead investor: 63%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/avego-management/
- Website: https://avego.com/

Avego Management is a VC fund in Alpharetta focused on Biotechnology and Pharmaceutical. Avego Management provides investment consultation for companies and capital investment assistance within the healthcare industry.

## Contacts

5 contacts available for Avego Management. Shizune tracks 2 team members at Avego Management. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/avego-management?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $40M–$197M |
| Series C | $120M–$120M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 38% |
| Pharmaceutical | 2 | 25% |
| Medical | 1 | 13% |
| Therapeutics | 1 | 13% |
| Manufacturing | 1 | 13% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 25% |
| Series C | 2 | 25% |
| Funding Round | 1 | 13% |
| Venture - Series Unknown | 1 | 13% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 38% |
| Canada | 1 | 13% |
| United Kingdom | 1 | 13% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Bala Venkataraman | Founding Partner | 0 | https://shizune.co/investors/profile/bala-venkataraman-8064 |
| Jerry Liao | Vice President | 2 | https://shizune.co/investors/profile/jerry-liao |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Alveus Therapeutics | Alveus Therapeutics is a clinical-stage biotech company developing therapies for obesity and metabolic diseases. | $197M | Series A | Jan 08, 2026 |  |
| CellCentric | CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga.The programme also has potential clinical utility in non-small cell lung, breast and colon cancer. | $120M | Series C | May 19, 2025 |  |
| AtomVie Global Radiopharma | AtomVie Global Radiopharma is a global Contract Development and Manufacturing Organization. It empowers next-generation radiotherapeutics and thrives to support its partners from early clinical development to commercial manufacturing. The company provides scientific, technical, regulatory, quality, logistics, and business expertise, as well as aspecialized infrastructure, allowing users to progress from Phase 1 to the commercial marketplace. | $90M | Series A | Jun 01, 2023 |  |
| PBS Biotech | PBS Biotech offers single-use bioreactors and process development services for cell product manufacturing. Their single-use bioreactors have the smallest per liter volume footprints and are fully scalable for any stage of the cell culture process, from R&D to clinical to cGMP production. They provide efficient, cost-effective disposable systemsand top-notch technical services to help their customers solve complex cell culture challenges. | $22M | Venture - Series Unknown | Jan 09, 2023 |  |
| Escient Pharmaceuticals | Escient Pharmaceuticals is a provider of bio-technical research and development services intended to focus in advancement of first-in-class G Protein-Coupled Receptor targeted drugs. The company's services focuses on offering therapies for neuro-immuno-inflammatory and autoreactive diseases, enabling its clients to receive drugs required fortreatment of serious, unserved medical needs across a broad range of therapeutic indications. | $120M | Series C | Nov 28, 2022 |  |
| AtomVie Global Radiopharma | AtomVie Global Radiopharma is a global Contract Development and Manufacturing Organization. It empowers next-generation radiotherapeutics and thrives to support its partners from early clinical development to commercial manufacturing. The company provides scientific, technical, regulatory, quality, logistics, and business expertise, as well as aspecialized infrastructure, allowing users to progress from Phase 1 to the commercial marketplace. | $40M | Series A | Aug 24, 2022 |  |
| AtomVie Global Radiopharma | AtomVie Global Radiopharma is a global Contract Development and Manufacturing Organization. It empowers next-generation radiotherapeutics and thrives to support its partners from early clinical development to commercial manufacturing. The company provides scientific, technical, regulatory, quality, logistics, and business expertise, as well as aspecialized infrastructure, allowing users to progress from Phase 1 to the commercial marketplace. | $40M | Series A | Aug 24, 2022 |  |
| PBS Biotech | PBS Biotech offers single-use bioreactors and process development services for cell product manufacturing. Their single-use bioreactors have the smallest per liter volume footprints and are fully scalable for any stage of the cell culture process, from R&D to clinical to cGMP production. They provide efficient, cost-effective disposable systemsand top-notch technical services to help their customers solve complex cell culture challenges. | $17M |  |  |  |

8 of 8 investments shown.

## Co-investors
- [BroadOak Capital Partners](https://shizune.co/investors/profile/broadoak-capital-partners) — VC Fund, 3 deals together
- [The Column Group](https://shizune.co/investors/profile/the-column-group) — VC Fund, 3 deals together
- [5AM Ventures](https://shizune.co/investors/profile/5am-ventures) — VC Fund, 1 deal together
- [Abingworth](https://shizune.co/investors/profile/abingworth-management) — VC Fund, 1 deal together
- [Altitude Life Science Ventures](https://shizune.co/investors/profile/altitude-life-science-ventures) — VC Fund, 1 deal together
- [BrightEdge - American Cancer Society](https://shizune.co/investors/profile/brightedge-american-cancer-society) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [Innova Memphis](https://shizune.co/investors/profile/innova-memphis) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Enterprise Ireland](https://shizune.co/investors/profile/enterprise-ireland) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [BDC Venture Capital](https://shizune.co/investors/profile/bdc-venture-capital) — VC Fund
- [Real Ventures](https://shizune.co/investors/profile/real-ventures) — VC Fund
- [Anges Quebec](https://shizune.co/investors/profile/anges-quebec) — VC Fund

## Featured in investor lists
- [Medical Device VC Funds in Canada](https://shizune.co/investors/medical-device-vc-funds-canada)

## FAQ

### What does Avego Management invest in?

Avego Management invests primarily in Biotechnology, Pharmaceutical and Medical startups, most often at Series A and Series C stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Avego Management's check size?

Avego Management typically joins rounds of $40M–$197M at Series A and $120M–$120M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Avego Management participates in.

### How do I contact Avego Management?

Public channels for Avego Management include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Avego Management?

The team at Avego Management includes Bala Venkataraman (Founding Partner) and Jerry Liao (Vice President). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co